−10.18USD
14.19 MUSD
17.98 MUSD
10.56 M
About Celularity Inc.
Sector
CEO
Robert Joseph Hariri Gordon
Website
Headquarters
Florham Park
Employees (FY)
225
Founded
2016
ISIN
US1511902041
FIGI
BBG00P2RTT34
Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert J. Hariri in 2016 and is headquartered in Florham Park, NJ.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of CELU is 3.10 USD — it has decreased by 3.43% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Celularity Inc. stocks are traded under the ticker CELU.
Celularity Inc. is going to release the next earnings report on May 14, 2024. Keep track of upcoming events with our Earnings Calendar.
CELU stock is 6.79% volatile and has beta coefficient of 3.35. Check out the list of the most volatile stocks — is Celularity Inc. there?
CELU earnings for the last quarter are 1.50 USD per share, whereas the estimation was −2.54 USD resulting in a 159.06% surprise. The estimated earnings for the next quarter are −2.40 USD per share. See more details about Celularity Inc. earnings.
Celularity Inc. revenue for the last quarter amounts to 4.13 M USD despite the estimated figure of 5.49 M USD. In the next quarter revenue is expected to reach 6.90 M USD.
Yes, you can track Celularity Inc. financials in yearly and quarterly reports right on TradingView.
CELU stock has fallen by 31.57% compared to the previous week, the month change is a 42.91% fall, over the last year Celularity Inc. has showed a 58.67% decrease.
CELU net income for the last quarter is −93.88 M USD, while the quarter before that showed −47.95 M USD of net income which accounts for −95.78% change. Track more Celularity Inc. financial stats to get the full picture.
Today Celularity Inc. has the market capitalization of 69.92 M, it has increased by 10.80% over the last week.
No, CELU doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, CELU shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Celularity Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 225.00 employees. See our rating of the largest employees — is Celularity Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Celularity Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Celularity Inc. stock shows the sell signal. See more of Celularity Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Celularity Inc. EBITDA is −87.94 M USD, and current EBITDA margin is −772.68%. See more stats in Celularity Inc. financial statements.